Luo Jingyi, Tu Shu, Li Kaijing, Yang Runcai, Lin Yixiu, Deng Jiayu, Chen Xiang, Ge Jian
State Key Laboratory of Ophthalmology, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, 510000, Guangdong, China.
Glaucoma Department, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, 510000, Guangdong, China.
Int Ophthalmol. 2025 Jul 21;45(1):305. doi: 10.1007/s10792-025-03693-1.
The study aimed to assess the neuroprotective effect of phospholipid-rich omega-3 fatty acids from herring caviar oil in POAG patients with intraocular pressure (IOP) control.
A single-center, observational, short-term, preliminary evaluation of three months was conducted. Fifty eyes of POAG patients with IOP were included and divided into the control group (n = 31) and the intervention group (n = 19) receiving one capsule of omega-3 fatty acids supplementation per day. All the participants underwent comprehensive clinical assessment at baseline and 3 months, including best-corrected visual acuity (BCVA), IOP, visual field (VF) test, optical coherence tomography (OCT). Primary outcomes were median deviation (MD) and pattern standard deviation (PSD) scores of VF, while secondary outcomes included BCVA, IOP, retinal nerve fiber layer thickness (RNFLT) of OCT, and adverse events.
At baseline, no significant differences were observed between the 50 patients in terms of age, sex, antiglaucomatous medications, BCVA, IOP, VF, or RNFLT. After three months, the intervention group exhibited a statistically significant improvement in MD value (p = 0.01). The change of PSD revealed a slightly greater reduction in the intervention group compared to controls, albeit with borderline significance (p = 0.08). A minor decrease in IOP was noted in the intervention group at three months, compared to the control group (p = 0.07). No significant differences were observed in other secondary outcomes, and no adverse events were reported.
Oral omega-3 fatty acids supplementation derived from herring caviar oil is potentially neuroprotective and safe for IOP-controlled POAG patients, and it may serve as a clinically valuable additional option. However, these results necessitate confirmation with an appropriately designed randomized controlled study.
本研究旨在评估鲱鱼鱼子酱油中富含磷脂的ω-3脂肪酸对眼压得到控制的原发性开角型青光眼（POAG）患者的神经保护作用。
进行了一项为期三个月的单中心、观察性、短期初步评估。纳入50只眼压得到控制的POAG患者的眼睛，并分为对照组（n = 31）和干预组（n = 19），干预组每天接受一粒ω-3脂肪酸补充剂胶囊。所有参与者在基线和3个月时均接受了全面的临床评估，包括最佳矫正视力（BCVA）、眼压、视野（VF）检查、光学相干断层扫描（OCT）。主要结局为视野的平均偏差（MD）和模式标准偏差（PSD）评分，次要结局包括BCVA、眼压、OCT的视网膜神经纤维层厚度（RNFLT）以及不良事件。
在基线时，50例患者在年龄、性别、抗青光眼药物、BCVA、眼压、视野或RNFLT方面未观察到显著差异。三个月后，干预组的MD值有统计学显著改善（p = 0.01）。PSD的变化显示，与对照组相比，干预组的降低幅度略大，尽管具有临界显著性（p = 0.08）。与对照组相比，干预组在三个月时眼压略有下降（p = 0.07）。在其他次要结局方面未观察到显著差异，且未报告不良事件。
口服源自鲱鱼鱼子酱油的ω-3脂肪酸补充剂对眼压得到控制的POAG患者可能具有神经保护作用且安全，并且可能是一种具有临床价值的额外选择。然而，这些结果需要通过适当设计的随机对照研究来证实。
